News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|December 22, 2022

Depression and Comorbid Health Conditions

Author(s)Gustavo Alva, MD, DFAPA, Charles Montano, MD, Carmen Kosicek, MSN, PMHNP-BC

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Episodes in this series

EP. 1 Impact of MDD Episode Duration and Recurrences

EP. 1 Impact of MDD Episode Duration and Recurrences

EP. 2 Depression and Comorbid Health Conditions

EP. 2 Depression and Comorbid Health Conditions

EP. 3 Perception of MDD in the Healthcare Community

EP. 3 Perception of MDD in the Healthcare Community

EP. 4 Monitoring Recommendations for MDD

EP. 4 Monitoring Recommendations for MDD

EP. 5 Treatment Options for MDD

EP. 5 Treatment Options for MDD

EP. 6 Treatment Approaches for Episodic and Chronic MDD

EP. 6 Treatment Approaches for Episodic and Chronic MDD

EP. 7 Current Challenges With MDD Treatment Options

EP. 7 Current Challenges With MDD Treatment Options

EP. 8 Impact of Different MDD Classes of Treatment on Time to Response

EP. 8 Impact of Different MDD Classes of Treatment on Time to Response

EP. 9 Unmet Needs in MDD Treatment Paradigm

EP. 9 Unmet Needs in MDD Treatment Paradigm

EP. 10 Key Takeaways for the Management of MDD

EP. 10 Key Takeaways for the Management of MDD

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Jennifer Payne, MD

Treating Mental Illness During Pregnancy the Same as Any Medical Illness: In Conversation With Jennifer L. Payne, MD

ByLeah Kuntz,Jennifer L. Payne, MD

October 15th 2025

adolescent depression seltorexant adjunct

Seltorexant Well-Tolerated in Adolescents as an Adjunct Treatment for Major Depressive Disorder

ByJessica Walters

October 13th 2025

nasal spray

Early Dose Management and Up-Titration of Esketamine: ECNP Poster Data

October 13th 2025

depression

New ECNP Poster Data on Adjunctive Lumateperone for Major Depressive Disorder

October 10th 2025

late life depression

Addressing Cognition in Late-Life Depression

ByJoshua J. Hubregsen, MD,Andre R. Brunoni, MD, PhD,Molly E. Camp, MD,Tarek K. Rajji, MD

October 1st 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Insomnia in Older Adults: A Holistic Approach

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

Reflections on the Therapeutic Alliance in Clinical Practice

Can a Class Action Lawsuit Force Big AI to Make Chatbots Safer?

How To Analyze a Randomized Controlled Trial

© 2025 MJH Life Sciences^®

All rights reserved.